Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 3No longer available 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Arthritis, Psoriatic 3Adenomatous Polyposis Coli 2

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × guselkumab × Clear all
NCT04936308 2026-06-05

SOLSTICE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
453 enrolled 25 charts

Arthritis, Psoriatic

NCT03649971 2025-02-03

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Janssen Research & Development, LLC

Phase 1 Completed
77 enrolled
Gastrointestinal

Adenomatous Polyposis Coli

NCT03796858 2025-02-03

COSMOS

Janssen Pharmaceutica N.V., Belgium

Phase 3 Completed
285 enrolled

Arthritis, Psoriatic

NCT04948398 2025-02-03

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Janssen Research & Development, LLC

No longer available
Gastrointestinal

Adenomatous Polyposis Coli

NCT03162796 2021-02-03

Discover-1

Janssen Research & Development, LLC

Phase 3 Completed
383 enrolled 106 charts

Arthritis, Psoriatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡